IMPAACT - International Maternal Pediatric Adolescence AIDS Clinical Trial Group (https://www.impaactnetwork.org/)

Ongoing studies:

P1093: Phase I/II Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability And Antiviral Activity Of Dolutegravir, A Novel Integrase Inhibitor, In Combination Regimens In Hiv-1 Infected Infants, Children And Adolescents (https://www.impaactnetwork.org/studies/p1093)

A5300 (B)/I2003(B)/PHOENIx: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) (A5300B/I2003B/PHOENIx) (https://www.impaactnetwork.org/studies/impaact2003ba5300b)

IMPAACT 2017: Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents (https://www.impaactnetwork.org/studies/impaact2017)

IMPAACT 2023: A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 (https://www.impaactnetwork.org/studies/impaact2023)

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum (https://www.impaactnetwork.org/studies/impaact2026)

IMPAACT P1115 V.2: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study (https://www.impaactnetwork.org/studies/p1115)

IMPAACT 2036/CRAYON: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV ≥2 to <12 years of age, and will also be known as the CRAYON Study (Cabotegravir and Rilpivirine Long-Acting Injections in YOung ChildreN) (https://www.impaactnetwork.org/studies/impaact2036)

ACTG - Advancing Clinical Therapeutics Globally (https://actgnetwork.org/)

Ongoing studies:

A5384: A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis (https://actgnetwork.org/clinical-trial/actg-a5384)

A5409: A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB) (https://actgnetwork.org/clinical-trial/a5409/)